UBS maintains Oragenics (AMEX:OGEN) with a Neutral and raises the price target from $31 to $39.
UBS Maintains Neutral on Oragenics, Raises Price Target to $39
UBS maintains Oragenics (AMEX:OGEN) with a Neutral and raises the price target from $31 to $39.
Benzinga · 11/15/2019 13:06